Search results for:

40 Post(s)

23 August 2021
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms

The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims to provide an assay to aid research on infections caused by Pseudomonas aeruginosa, delivering a solution to accelerate wound care research and reduce the reliance on mammalian testing. The project focuses on developing an industrial whole organism assay for biofilms […]

Read More
29 July 2021
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand

Durham, UK - July 29, 2021 Magnitude Biosciences, the world’s leading commercial lab services provider in using the nematode worm C. elegans to accelerate drug discovery and other research in the areas of the gut microbiome, ageing, and neurodegeneration, today announced the addition of two members to its growing project delivery team in the lab: […]

Read More
26 July 2021
Could C. elegans be the key to slowing ageing?

Originally published in Health Tech World: https://www.htworld.co.uk/interviews/could-c-elegans-be-the-key-to-slowing-ageing/ Health Tech World spoke to Magnitude Biosciences about its groundbreaking work with C. elegans and how it is assisting biotechs in the development of drugs that can slow ageing and tackle age-related neurodegenerative diseases.  C. elegans is a tiny worm about a millimetre in length. It’s been used in research since […]

Read More
19 July 2021
Frontiers in Longevity: How do we slow human ageing?

How do we slow the process of Ageing? David Weinkove discusses learnings from the Clubhouse event "The Future of Longevity II"

Read More
16 July 2021
Unlocking the microbiome as a target for drug discovery using C. elegans

The human microbiome holds great promise for modern medicine but is still largely a mystery to scientists

Read More
15 July 2021
C. elegans to accelerate industrial drug discovery and address the costs and challenges of early preclinical research

Magnitude Bioscience CEO, David Weinkove, discusses the application of C. elegans to accelerate the industrial drug discovery process

Read More
9 July 2021
Translating groundbreaking drug development ideas into therapies with worms: takeaways from the joint ELRIG and British Pharmacological Society 2021 meeting

Some fascinating ideas came out of the Translating Ideas Into Therapies meeting held June 30-July 1 2021 by ELRIG and the British Pharmacological Society

Read More
5 July 2021
Developing a System to Quantify Efficacy of Neurodegeneration Therapeutics Using Automated Monitoring of C. elegans

Check out our poster showing how we can quantify the efficacy of neurodegeneration models

Read More
21 June 2021
Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control satiety

Neuronal SKN-1B modulates nutritional signalling pathways and mitochondrial networks to control satiety Related Resources

Read More
21 June 2021
Chemosensory Neurons Modulate the Response to Oomycete Recognition in Caenorhabditis elegans

The Barkoulas Lab, including our own Michael Fasseas , find an Oomycetes recognition response in C. elegans which leads to a reduction in the attachment of pathogens with applications for immunity and animal survival. Related Resources

Read More

CONTACT US

Get in touch today to find out how we can 
support you to accelerate your research

© 2025 Magnitude Biosciences Ltd. All rights reserved.

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram